Li-Han Lin

Dr. Li-Han Lin

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
LLLi-Han Lin
Li-Han Lin
KCKuo-Wei Chang
Kuo-Wei Chang
SKShou-Yen Kao
Shou-Yen Kao
HCHui-Wen Cheng
Hui-Wen Cheng
CLChung Ji Liu
Chung Ji Liu
Background: Oral squamous cell carcinoma (OSCC) is a disease that affects patients worldwide. DNA of dead cells is released into the blood stream and may be isolated from plasma or serum samples. This DNA is termed cell-free DNA (cfDNA). cfDNA is increased in several types of malignancies. We investigated if there was a correlation between cfDNA levels and the progression of OSCC. Methods: Using quantitative spectrometry, we measured plasma cfDNA in 121 patients with OSCC and 50 matched controls. Mann Whitney and Wilcoxon tests were used to compare differences among various clinical variants. Receiver operating characteristic (ROC) analysis was used to obtain levels suitable for the separation of the clinical subsets. Kaplan-Meier analysis was used to assess correlation with survival. Results: Plasma cfDNA was significantly elevated in patients with OSCC relative to controls. Plasma cfDNA levels correlated with larger tumor size, cervical lymph node metastasis and late stage. Higher plasma cfDNA levels were associated with a poor prognosis of OSCC, which is a new finding. Conclusion: Plasma cfDNA could serve as a novel and easily accessible biomarker in OSCC, providing diagnostic and prognostic value.

Verified
Journal Article
Open access
PDF file
LLLi-Han Lin
Li-Han Lin
JLJiun-Sheng Lin
Jiun-Sheng Lin
CYCheng-Chieh Yang
Cheng-Chieh Yang
HCHui-Wen Cheng
Hui-Wen Cheng
KCKuo-Wei Chang
Kuo-Wei Chang
CLChung Ji Liu
Chung Ji Liu
Oral squamous cell carcinoma (OSCC) is a cancerous disease with poor prognosis. According to the statistics, the 5-year survival rate has not improved significantly over the past 20 years. The platelet-derived growth factor (PDGF) and its signaling pathway is a key regulator of angiogenesis and tumorigenesis. High level of PDGF and its receptor (PDGFR) have been reported in several types of malignancies. In this study, we investigated the relationship of the molecular expression levels of PDGF and PDGFR with clinicopathological parameters in OSCC. To this end, we measured the mRNA and protein levels of PDGF and PDGFR by real-time quantitative PCR (qRT-PCR), immunohistochemistry, and enzyme-linked immunosorbent assay (ELISA), respectively. We found positive correlations of the mRNA levels of PDGFA, PDGFB, and PDGFRB with lymph node metastasis and poor overall survival (OS). High expression of PDGF, PDGFRA, and PDGFRB were remarkably associated with lymph node metastasis and poor OS, as determined by immunohistochemistry. Preoperative serum levels of PDGF-AA and PDGF-BB had a positive correlation with preoperative platelet count. Elevated serum levels of PDGF-AA. PDGF-BB, and platelet count correlated with lymph node metastasis and an unfavorable outcome. In multivariate Cox regression analysis, PDGFA mRNA, PDGFB mRNA, PDGFRB mRNA, PDGF immunoexpression, PDGFRB immunoexpression, serum PDGF-AA, serum PDGF-BB, and platelet count emerged as significant independent prognostic factors for OS. In vitro, we found that elevated PDGF promotes colony formation, migration, and invasiveness of SAS and OECM-1 cancer cell lines. Our results suggest that the expression level of serum PDGF has the potential to become a useful diagnostic marker for the prognosis of OSCC. In addition, PDGFR should be considered as a potential therapeutic target for OSCC. Furthermore, research should be undertaken to elucidate the role of PDGF and PDGFR regarding the behavior of tumor cells in OSCC.

Verified
Journal Article
Open access
PDF file
LLLi-Han Lin
Li-Han Lin
KCKuo-Wei Chang
Kuo-Wei Chang
HCHui-Wen Cheng
Hui-Wen Cheng
CLChung Ji Liu
Chung Ji Liu
The accurate diagnosis and treatment of oral squamous cell carcinoma (OSCC) requires an understanding of its genomic alterations. Liquid biopsies, especially cell-free DNA (cfDNA) analysis, are a minimally invasive technique used for genomic profiling. We conducted comprehensive whole-exome sequencing (WES) of 50 paired OSCC cell-free plasma with whole blood samples using multiple mutation calling pipelines and filtering criteria. Integrative Genomics Viewer (IGV) was used to validate somatic mutations. Mutation burden and mutant genes were correlated to clinico-pathological parameters. The plasma mutation burden of cfDNA was significantly associated with clinical staging and distant metastasis status. The genes TTN, PLEC, SYNE1, and USH2A were most frequently mutated in OSCC, and known driver genes, including KMT2D, LRP1B, TRRAP, and FLNA, were also significantly and frequently mutated. Additionally, the novel mutated genes CCDC168, HMCN2, STARD9, and CRAMP1 were significantly and frequently present in patients with OSCC. The mutated genes most frequently found in patients with metastatic OSCC were RORC, SLC49A3, and NUMBL. Further analysis revealed that branched-chain amino acid (BCAA) catabolism, extracellular matrix–receptor interaction, and the hypoxia-related pathway were associated with OSCC prognosis. Choline metabolism in cancer, O-glycan biosynthesis, and protein processing in the endoplasmic reticulum pathway were associated with distant metastatic status. About 20% of tumors carried at least one aberrant event in BCAA catabolism signaling that could possibly be targeted by an approved therapeutic agent. We identified molecular-level OSCC that were correlated with etiology and prognosis while defining the landscape of major altered events of the OSCC plasma genome. These findings will be useful in the design of clinical trials for targeted therapies and the stratification of patients with OSCC according to therapeutic efficacy.

12 June 2023 in Journal of Dental Sciences
Verified
Journal Article
Open access
HCHao-Wen Chuang
Hao-Wen Chuang
LLLi-Han Lin
Li-Han Lin
DJDar-Der Ji
Dar-Der Ji
TFTing-Ying Fu
Ting-Ying Fu
HLHerng-Sheng Lee
Herng-Sheng Lee
KHKan-Tai Hsia
Kan-Tai Hsia
The serpin peptidase inhibitor, clade E, member 2 (SERPINE2), is upregulated in breast cancer, prostate cancer, and urothelial carcinoma; however, limited information exists regarding its expression in oral cancer. Therefore, this study aimed to analyze the association between SERPINE2 expression and oral squamous cell carcinoma (OSCC) outcomes. SERPINE2 mRNA and protein expression in patients with head and neck squamous cell carcinoma and OSCC were investigated using online databases and tissue-array analysis. Its relationship with clinicopathological characteristics, OSCC prognosis and its biological function in OSCC cells were explored. Analysis using online databases revealed higher SERPINE2 expression in tumor tissues and its role as a prognostic factor. High SERPINE2 protein levels were significantly correlated with adverse pathological parameters, including advanced clinical stage and tumor status (P < 0.001), lymph nodes (P = 0.014), and distant metastases (P = 0.013). High SERPINE2 expression was associated with worse overall survival (P < 0.001) and was identified as an independent prognostic factor for OSCC. In vitro studies revealed that SERPINE2 knockdown significantly reduced cell proliferation, migration, and invasion in OSCC cell lines. This study suggests that SERPINE2 may serve as a prognostic biomarker and potential therapeutic target for oral cancer.

1 January 2022 in International Journal of Neurosurgery
Verified
Journal Article
Open access
PDF file
KCKai-Jie Chia
Kai-Jie Chia
CRCheng-Shyuan Rau
Cheng-Shyuan Rau
WCWu-Fu Chen
Wu-Fu Chen
LLLi-Han Lin
Li-Han Lin
JLJui-Wei Lin
Jui-Wei Lin
JHJih-Jun Ho
Jih-Jun Ho
Central neurocytoma (CN) is a rare and elusive tumor. The relationship between clinical outcome, tumor nature, and treatment of CN remains controversial. There were eight CN patients in our hospital from 2014 to 2021, and the prevalence of CN accounted for 0.36% of brain tumors. All of them underwent surgical removal, and two of them were combined with adjuvant radiotherapy (RT). We found that four patients without surgical complications had small tumors (33.0 ± 19.5 cm³), while the other four patients with surgical complications had larger tumors (89.8 ± 14.2 cm³). This suggests that large tumors are prone to surgical complications. One particular patient with a large CN suffered from intraventricular hemorrhage (IVH) caused by damage to the internal cerebral vein (figure 3). Regarding the effect of total removal (TR) and subtotal removal (SR) on surgical complications, two patients with large CNs died of IVH after TR. However, two other patients with large CN had a good prognosis after SR. Regarding the effect of adjuvant RT on surgical complications, one patient with large CN who received RT after SR and one patient with atypical small CN (MIB-1 LI 5.3%) who received RT after TR had a good prognosis without recurrence. Therefore, we suggest SR combined with RT for large CNs in the deep-site ventricle, TR for small CNs, and TR combined with RT for atypical small CNs. Clinical features of patients due to hydrocephalus subsided after surgical treatment. We also review literature and discuss clinical outcomes and treatment associated with CNs. Further investigation with a larger sample size is warranted for the optimal treatment.